Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mallinckrodt Plc (MNKKQ)

Mallinckrodt Plc (MNKKQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,696
  • Shares Outstanding, K 84,783
  • Annual Sales, $ 1,914 M
  • Annual Income, $ -911,200 K
  • 60-Month Beta 2.72
  • Price/Sales 0.00
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MNKKQ with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.86
  • Most Recent Earnings $-0.95 on 05/03/22
  • Latest Earnings Date 06/27/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0010 +1,900.00%
on 06/13/22
0.0999 -79.98%
on 05/19/22
-0.0585 (-74.52%)
since 05/16/22
3-Month
0.0010 +1,900.00%
on 06/13/22
0.1300 -84.62%
on 04/18/22
-0.0980 (-83.05%)
since 03/16/22
52-Week
0.0010 +1,900.00%
on 06/13/22
0.5895 -96.61%
on 06/22/21
-0.3630 (-94.78%)
since 06/16/21

Most Recent Stories

More News
Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome

/PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced the resubmission of the Company's New Drug Application...

MNKKQ : 0.0200 (+10.50%)
Mallinckrodt Announces Anticipated Chapter 11 Emergence and Provides Update on Trading of New Ordinary Shares

/PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that it expects to complete its reorganization process,...

MNKKQ : 0.0200 (+10.50%)
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501

Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant...

SLN : 22.95 (+1.55%)
MNKKQ : 0.0200 (+10.50%)
Buxton Helmsley Publicly Responds to Departure of Mallinckrodt Plc. CCO, After Open Letter to U.S. SEC Detailing Accounting Fraud

The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with significant holdings of Mallinckrodt...

OTC.VN : 0.325 (+6.56%)
MNKKQ : 0.0200 (+10.50%)
Buxton Helmsley Publicly Responds to Resignation of Mallinckrodt Plc. SVP, Finance, Days After Open Letter to U.S. SEC Detailing Accounting Fraud

The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with significant holdings of Mallinckrodt...

OTC.VN : 0.325 (+6.56%)
MNKKQ : 0.0200 (+10.50%)
The Buxton Helmsley Group Calls on U.S. Securities and Exchange Commission to Intervene in Mallinckrodt Plc. Fraud Involving False Statements of Financials, Insider Trading on Undisclosed Information, and Electoral Tampering

The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with significant holdings of Mallinckrodt...

OTC.VN : 0.325 (+6.56%)
MNKKQ : 0.0200 (+10.50%)
Mallinckrodt Presents Results on Real World Treatment Patterns and Outcomes in Hospitalized Patients with Esophageal Variceal Hemorrhage and Liver Cirrhosis Treated with Terlipressin at the American College of Gastroenterology Annual Scientific Meeting

/PRNewswire/ -- Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results from a retrospective medical chart review study...

MNKKQ : 0.0200 (+10.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media...

See More

Key Turning Points

3rd Resistance Point 0.0316
2nd Resistance Point 0.0282
1st Resistance Point 0.0241
Last Price 0.0200
1st Support Level 0.0166
2nd Support Level 0.0132
3rd Support Level 0.0091

See More

52-Week High 0.5895
Fibonacci 61.8% 0.3647
Fibonacci 50% 0.2952
Fibonacci 38.2% 0.2258
Last Price 0.0200
52-Week Low 0.0010

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar